Evidence map›Paper›PMID 37587291›Full record

ArticleDrug delivery and translational research2024

Modulation of microglial polarization by sequential targeting surface-engineered exosomes improves therapy for ischemic stroke.

Xintong Liu, Yunni Hao, Zhixuan Huang, Yijie Shi, Chang Su, Liang Zhao

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xintong LiuSchool of Pharmacy, Jinzhou Medical University, Jinzhou, 121000, People's Republic of China.
Yunni HaoSchool of Pharmacy, Jinzhou Medical University, Jinzhou, 121000, People's Republic of China.
Zhixuan HuangSchool of Pharmacy, Jinzhou Medical University, Jinzhou, 121000, People's Republic of China.
Yijie ShiSchool of Pharmacy, Jinzhou Medical University, Jinzhou, 121000, People's Republic of China.
Chang SuSchool of Veterinary Medicine, Jinzhou Medical University, Jinzhou, 121000, People's Republic of China.
Liang ZhaoSchool of Pharmacy, Jinzhou Medical University, Jinzhou, 121000, People's Republic of China. liangzhao79@163.com.ORCID 0000-0002-3464-6956
Jinzhou Medical University · CN

Funding

Project of Liaoning Educational Committee JYTJCZR2020067Project of Liaoning Educational Committee JYTQN2020015
6 · The paper itself

Abstract

Microglia are important cells that act on regulating neuroinflammation and neurofunction after the induction of ischemic stroke (IS). Consequently, the efficient accumulation of drugs within ischemic regions, particularly in microglia, serves as a valuable approach for achieving effective therapy by attenuating microglia-mediated cerebral ischemic injury. In this study, we designed mannose (man)-conjugated luteolin (lut)-loaded platelet-derived exosomes (lut/man-pEXO) as surface engineered multifunctional cascade-delivery drug carriers to target ischemic blood vessels and subsequent microglia to enhance drug accumulation and induce neuroprotection of neurovascular unit (NVU) against IS. The results revealed that as platelets naturally gathered in pathological ischemic cerebral vessels, lut/man-pEXO could bind to platelets and efficiently target ischemic injury sites. Moreover, owing to the selective binding affinity of mannose present in lut/man-pEXO towards the mannose receptor expressed on microglia, lut/man-pEXO exhibited superior microglia-targeting properties, inducing the increased uptake of lut by microglia. As a result, lut/man-pEXO regulated microglia by inhibiting the activation of detrimental M1 and promoting the transition towards the anti-inflammatory type (M2), thus attenuating ischemic damage of NVU by reducing the infarct area, rescuing the damage of blood-brain barrier (BBB) and preventing inflammatory transformation of astrocytes.

Indexed as

Brain IschemiaExosomesIschemic StrokeStrokeHumansMannoseMicrogliaMannoseLuteolinMannoseMicrogliaPlatelet-derived exosomes

Identifiers

PMID37587291
OpenAlexW4385858065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.